The newly issued patent, namely, ‘Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases,’ includes the usage of oral lactoferrins, including talactoferrin, to treat cancer.
The patent, which will be expired in 2023, also covers the usage of talactoferrin in conjunction with other therapies, including chemotherapy, immunotherapy, radiation therapy and other treatments.
Agennix chief financial officer Torsten Hombeck said this European patent provides protection for talactoferrin in this key market, as it covers the use of human lactoferrin for oral administration, used alone or in combination with other therapies, for the treatment of all cancer types.
"We also have cancer use patents that were recently issued in the US and Japan, two of the other major markets for talactoferrin, that provide protection until 2025 and 2023, respectively, and include coverage for our lead indication, non-small cell lung cancer," Hombeck said.